Update of systemic immunotherapy for advanced urothelial carcinoma

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

“…The 5‐y survival rate for all patients diagnosed with bladder cancer is 77%, but falls to 36% for those with disease that spreads to regional lymph nodes and to <5% for those with distant metastases 1 . Until recently, initial treatments for patients with metastatic UC have been limited to platinum‐based chemotherapy 2 . Median OS was reported as between 14.1 and 15.5 mo for patients who received cisplatin‐containing regimens 3,4 and 13.8 mo for patients who received carboplatin‐containing regimens 3 .…”

“…1 Until recently, initial treatments for patients with metastatic UC have been limited to platinum-based chemotherapy. 2 Median OS was reported as between 14.1 and 15.5 mo for patients who received cisplatin-containing regimens 3,4 and 13.8 mo for patients who received carboplatin-containing regimens. 3 For patients ineligible for cisplatin-containing regimens, median survival was only 8-9 mo with carboplatin-based combination chemotherapy.…”

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

“…Genomic profiling was also conducted for exploratory biomarker analysis using the FoundationOne panel (72). Treatment with atezolizumab resulted in improved survival, with higher levels of PD-L1 expression on immune cells, though not with tumor cells, or higher TMB associated with higher response rate (73,74). PD-L1 expression was then incorporated into FDA labeling in 2018 following the IMvigor210 clinical trial, to select patients who should receive Tecentriq treatment (74,75).…”

“…Treatment with atezolizumab resulted in improved survival, with higher levels of PD-L1 expression on immune cells, though not with tumor cells, or higher TMB associated with higher response rate (73,74). PD-L1 expression was then incorporated into FDA labeling in 2018 following the IMvigor210 clinical trial, to select patients who should receive Tecentriq treatment (74,75). Tumor specimens were prospectively evaluated using the Ventana PD-L1 (SP142) assay and patients with high levels of PD-L1 expression had improved PR, CR, and ORR.…”

New treatment options for advanced urothelial cancer: a combination of atesolizumab with chemotherapy

“…Ингибиторы контрольных точек иммунитета являются первым новым классом препаратов, показавшим большую эффективность в 1-й линии терапии пациентов с метастатическим уротелиальным раком с противопоказанием к применению цисплатина и во 2-й линии у пациентов с прогрессированием заболевания на фоне ХТ на основе платины [5][6][7][8][9][10][11][12]. Комбинированные схемы, сочетающие ХТ на основе платины и ингибиторы PD-L1 и PD-1, привлекательны по нескольким причинам.…”